JP2013515698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515698A5 JP2013515698A5 JP2012545331A JP2012545331A JP2013515698A5 JP 2013515698 A5 JP2013515698 A5 JP 2013515698A5 JP 2012545331 A JP2012545331 A JP 2012545331A JP 2012545331 A JP2012545331 A JP 2012545331A JP 2013515698 A5 JP2013515698 A5 JP 2013515698A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- group
- methyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 33
- 150000003839 salts Chemical class 0.000 claims 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- -1 4 - ((2-adamantylmethyl) methyl) -6- (3 -(Methylamino) azetidin-1-yl) pyrimidin-2-amine Chemical compound 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- LLSSPZDMUUXVCW-UHFFFAOYSA-N 4-[(cyclopentylamino)methyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2-amine Chemical compound C1C(NC)CN1C1=CC(CNC2CCCC2)=NC(N)=N1 LLSSPZDMUUXVCW-UHFFFAOYSA-N 0.000 claims 2
- RKBNBAJKYBTOQZ-UHFFFAOYSA-N 4-[(cyclopropylmethylamino)methyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2-amine Chemical compound C1C(NC)CN1C1=CC(CNCC2CC2)=NC(N)=N1 RKBNBAJKYBTOQZ-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 2
- RTTSWILDBDDABZ-UHFFFAOYSA-N 4-[(tert-butylamino)methyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2-amine Chemical compound C1C(NC)CN1C1=CC(CNC(C)(C)C)=NC(N)=N1 RTTSWILDBDDABZ-UHFFFAOYSA-N 0.000 claims 1
- XSGFQLUNZSOVEQ-UHFFFAOYSA-N 4-[3-(methylamino)azetidin-1-yl]-6-[(2,2,2-trifluoroethylamino)methyl]pyrimidin-2-amine Chemical compound C1C(NC)CN1C1=CC(CNCC(F)(F)F)=NC(N)=N1 XSGFQLUNZSOVEQ-UHFFFAOYSA-N 0.000 claims 1
- PLWRKPDLWQRXEK-UHFFFAOYSA-N 4-[3-(methylamino)azetidin-1-yl]-6-[(2-methylpropylamino)methyl]pyrimidin-2-amine Chemical compound C1C(NC)CN1C1=CC(CNCC(C)C)=NC(N)=N1 PLWRKPDLWQRXEK-UHFFFAOYSA-N 0.000 claims 1
- OGMDUKATGXIUEA-UHFFFAOYSA-N 4-[3-(methylamino)azetidin-1-yl]-6-[(pentylamino)methyl]pyrimidin-2-amine Chemical compound NC1=NC(CNCCCCC)=CC(N2CC(C2)NC)=N1 OGMDUKATGXIUEA-UHFFFAOYSA-N 0.000 claims 1
- RWTXOMRUFONLJO-UHFFFAOYSA-N 4-[3-(methylamino)azetidin-1-yl]-6-[(propan-2-ylamino)methyl]pyrimidin-2-amine Chemical compound C1C(NC)CN1C1=CC(CNC(C)C)=NC(N)=N1 RWTXOMRUFONLJO-UHFFFAOYSA-N 0.000 claims 1
- KNAYTBMVIPRJDN-UHFFFAOYSA-N 4-[[(2,2-diethylcyclopropyl)methylamino]methyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2-amine Chemical compound CCC1(CC)CC1CNCC1=CC(N2CC(C2)NC)=NC(N)=N1 KNAYTBMVIPRJDN-UHFFFAOYSA-N 0.000 claims 1
- NEYYFVIUAGGKFC-VIFPVBQESA-N 4-[[[(2s)-butan-2-yl]amino]methyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2-amine Chemical compound NC1=NC(CN[C@@H](C)CC)=CC(N2CC(C2)NC)=N1 NEYYFVIUAGGKFC-VIFPVBQESA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382302 | 2009-12-23 | ||
| EP09382302.9 | 2009-12-23 | ||
| US30757910P | 2010-02-24 | 2010-02-24 | |
| US61/307,579 | 2010-02-24 | ||
| PCT/EP2010/070562 WO2011076878A1 (en) | 2009-12-23 | 2010-12-22 | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515698A JP2013515698A (ja) | 2013-05-09 |
| JP2013515698A5 true JP2013515698A5 (OSRAM) | 2014-02-20 |
| JP5781537B2 JP5781537B2 (ja) | 2015-09-24 |
Family
ID=41667549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012545331A Active JP5781537B2 (ja) | 2009-12-23 | 2010-12-22 | ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8901146B2 (OSRAM) |
| EP (1) | EP2516420B8 (OSRAM) |
| JP (1) | JP5781537B2 (OSRAM) |
| KR (1) | KR101740085B1 (OSRAM) |
| CN (1) | CN102803248B (OSRAM) |
| AR (1) | AR079725A1 (OSRAM) |
| AU (1) | AU2010334804B2 (OSRAM) |
| BR (1) | BR112012017126A2 (OSRAM) |
| CA (1) | CA2785353C (OSRAM) |
| IL (1) | IL220554A (OSRAM) |
| MX (1) | MX345142B (OSRAM) |
| NZ (1) | NZ601021A (OSRAM) |
| PE (1) | PE20121505A1 (OSRAM) |
| RU (1) | RU2573828C2 (OSRAM) |
| TW (1) | TWI487697B (OSRAM) |
| UA (1) | UA107818C2 (OSRAM) |
| WO (1) | WO2011076878A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010311378B2 (en) | 2009-10-29 | 2014-04-24 | Vectura Limited | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |
| SI3513793T1 (sl) * | 2011-09-02 | 2021-07-30 | Incyte Holdings Corporation | Heterociklilamini kot zaviralci PI3K |
| EP3697776B1 (en) | 2017-10-17 | 2023-04-19 | Palau Pharma, S.L.U. | Synthesis of 4-aminopyrimidine compounds |
| GB201817047D0 (en) | 2018-10-19 | 2018-12-05 | Heptares Therapeutics Ltd | H4 antagonist compounds |
| JP2022165429A (ja) * | 2019-10-02 | 2022-11-01 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ヒスタミンｈ４受容体調節作用を有する新規トリアジン誘導体 |
| CN117018194A (zh) * | 2023-07-26 | 2023-11-10 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9813938A (pt) * | 1997-11-04 | 2000-09-26 | Pfizer Prod Inc | Compostos terapeuticamente ativos baseados na substituição bioisóstera de indazol por catecol em inibidores de pde4 |
| JP4681451B2 (ja) * | 2002-10-28 | 2011-05-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類 |
| EP1568688B1 (en) * | 2002-11-25 | 2011-08-31 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient |
| EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
| WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| CA2604890A1 (en) * | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use for the treatment of cancer |
| RU2008114378A (ru) | 2005-09-13 | 2009-10-20 | Палау Фарма, С.А. (Es) | Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина |
| MY167260A (en) * | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| US20100035863A1 (en) | 2006-09-12 | 2010-02-11 | Ucb Pharma, S.A. | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
| WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| AR069813A1 (es) | 2007-12-19 | 2010-02-17 | Palau Pharma Sa | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
| PT2235012E (pt) * | 2007-12-21 | 2013-08-28 | Palau Pharma Sa | Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina |
-
2010
- 2010-12-22 AR ARP100104921A patent/AR079725A1/es not_active Application Discontinuation
- 2010-12-22 UA UAA201207986A patent/UA107818C2/uk unknown
- 2010-12-22 WO PCT/EP2010/070562 patent/WO2011076878A1/en not_active Ceased
- 2010-12-22 CN CN201080064585.3A patent/CN102803248B/zh active Active
- 2010-12-22 BR BR112012017126A patent/BR112012017126A2/pt not_active Application Discontinuation
- 2010-12-22 JP JP2012545331A patent/JP5781537B2/ja active Active
- 2010-12-22 NZ NZ601021A patent/NZ601021A/en unknown
- 2010-12-22 RU RU2012131223/04A patent/RU2573828C2/ru active
- 2010-12-22 PE PE2012000880A patent/PE20121505A1/es not_active Application Discontinuation
- 2010-12-22 CA CA2785353A patent/CA2785353C/en active Active
- 2010-12-22 TW TW099145246A patent/TWI487697B/zh active
- 2010-12-22 KR KR1020127019521A patent/KR101740085B1/ko active Active
- 2010-12-22 MX MX2012007385A patent/MX345142B/es active IP Right Grant
- 2010-12-22 EP EP10799037.6A patent/EP2516420B8/en active Active
- 2010-12-22 US US13/518,729 patent/US8901146B2/en active Active
- 2010-12-22 AU AU2010334804A patent/AU2010334804B2/en active Active
-
2012
- 2012-06-21 IL IL220554A patent/IL220554A/en active IP Right Grant